IND Approval from the US FDA for Theranostic SAR-Bombesin Trial in Prostate Cancer

Clarity Pharmaceuticals announced the approval of its Investigational New Drug (IND) application by the US FDA to evaluate its SAR-Bombesin product for identification and treatment of metastatic castrate-resistant prostate cancer.
[Clarity Pharmaceuticals]
Press Release
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News